ALS drug sets the stage for fresh FDA de­bate; Im­plo­sions every­where you look; Big names turn up at biotechs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In­ter­est­ed in men­tal health? My col­league Nicole De­Feud­is is host­ing a vir­tu­al pan­el next week on how a new brand of biotech is out to use mod­i­fied psy­che­delics to rewire the brain in search of new and bet­ter ther­a­pies. You can at­tend at no cost and it promis­es to be a dy­nam­ic con­ver­sa­tion. Check it out here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER